Lyell Immunopharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Lyell Immunopharma, Inc. (LYEL) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-342.99-234.63-183.12-250.22-204.47
Depreciation & Amortization19.6320.2518.0215.534.29
Stock Based Compensation33.1447.0881.9262.2033.26
Change in Working Capital-3.123.42-82.02-9.50-0.34
Change in Accounts Payable-3.231.460.670.09-0.28
Change in Other Working Capital80.02-4.651.974.627.70
Other Operating Activities80.02-4.65-5.62115.8210.72
Net Cash from Operating Activities-162.39-163.69-169.56-126.25-160.87
Investing Activities
Capital Expenditures-0.46-2.69-24.2865.50-51.48
Acquisitions-31.350.000.000.000.00
Purchases of Investments-394.71-476.8812.74-673.47-222.04
Sales/Maturities of Investments548.94663.6112.74-56.070.00
Net Cash from Investing Activities122.42184.05-11.54-121.57-273.52
Financing Activities
Common Stock Issued1.402.2011.10391.800.37
Common Stock Repurchased0.00-0.46-0.460.00-11.81
Other Financing Activities-0.08-0.46-0.460.910.00
Net Cash from Financing Activities1.331.7410.64401.24476.79
Summary
Net Change in Cash-38.6422.10-170.46153.4242.40
Cash at Beginning of Period145.93123.83294.29140.870.00
Cash at End of Period107.29145.93123.83294.290.00
Free Cash Flow-162.86-166.38-193.83-191.75-212.36